GH Research Reports 73% Remission in TRD with GH001; Global Pivotal Trial Set for 2026

Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months...

July 25, 2025 | Friday | News
Korean Study Reveals Toxic Effects of Airborne Fungi at Levels Below Current Guidelines

Airborne microorganisms, including fungi and bacteria, are major contributors to indoor air pollution, with growing links to respiratory diseases. In a r...

July 18, 2025 | Friday | Reports
Imugene Reports 75% Overall Response Rate in U.S.–Australia Phase 1b Trial of Off-the-Shelf CAR T Therapy for Relapsed DLBCL

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall R...

July 15, 2025 | Tuesday | News
Physician Perceptions Shift as Retina Treatment Market Braces for Disruption from Payers and Pipeline Innovations

Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related macular degene...

July 11, 2025 | Friday | News
Abinopharm Reports Positive Clinical Trial Outcomes for Oral Dr.Ergo® L-Ergothioneine in Enhancing Skin Health

Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EG...

July 07, 2025 | Monday | News
Asahi Kasei Pharma Begins Phase III Trial in Japan of ART-123 for Preventing Chemotherapy-Induced Peripheral Neuropathy

Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic name: thrombomodulin alfa; marketed as Recomod...

July 03, 2025 | Thursday | News
JCR Pharmaceuticals Completes Enrollment in Global Phase III Trial of JR-141 for Hunter Syndrome Across the U.S., Latin America, and Europe

-JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III cli...

July 03, 2025 | Thursday | News
Artelo Biosciences Reports Positive First-in-Human Data for ART26.12, a First-in-Class FABP5 Inhibitor Targeting Chronic Pain

Artelo Biosciences, Inc. a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people liv...

July 01, 2025 | Tuesday | News
Mabion and NovalGen Forge Strategic Partnership to Advance First-in-Class T-Cell Engager NVG-222 Into Clinical Trials

In a significant move to accelerate the global fight against blood cancers and hard-totreat solid tumours, renowned end- to-end biologics CDMO Mabion hav...

June 30, 2025 | Monday | News
Noxopharm Advances HERACLES Trial with Rapid Recruitment for First-in-Human SOF-SKN™ Study in Autoimmune Diseases

Clinical-stage biotech company Noxopharm Limited (ASX:NOX) is pleased to announce that recruitment activities are progressing rapidly and on sche...

June 25, 2025 | Wednesday | News
Thermosome Reports Promising Phase I Results for THE001 and Regional Hyperthermia in Soft Tissue Sarcoma Patients

Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Ph...

June 24, 2025 | Tuesday | News
EXACT Therapeutics Doses First Patient in Phase 2 ENACT Trial for Pancreatic Cancer

EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial. ...

June 24, 2025 | Tuesday | News
Lilly’s Once-Weekly Efsitora Matches Daily Insulin in Phase 3 Trials, Global Filing Planned by Year-End

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with...

June 23, 2025 | Monday | Reports
Ipsen’s Cabometyx® Receives Positive CHMP Opinion for Advanced Neuroendocrine Tumors

Ipsen  announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion...

June 23, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close